Amicus Therapeutics Inc (FOLD)

6.87
0.11 1.60
NASDAQ : Health Care
Prev Close 6.98
Open 7.01
Day Low/High 6.65 / 7.10
52 Wk Low/High 4.98 / 18.40
Volume 513.42K
Avg Volume 2.40M
Exchange NASDAQ
Shares Outstanding 142.14M
Market Cap 992.13M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Amicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines'

Amicus (FOLD) CEO Crowley to CNBC: 'Our Job is to Stay Focused and Keep Making Great Medicines'

Amicus Therapeutics (FOLD) CEO John Crowley joined Thursday morning's 'Squawk Box' on CNBC to discuss the future of the company and new medications in the pipeline.

Amicus Therapeutics (FOLD) Stock Slumps on Q2 Loss

Amicus Therapeutics (FOLD) Stock Slumps on Q2 Loss

Amicus Therapeutics (FOLD) reported a wider-than-expected loss for the 2016 second quarter before Tuesday's market open.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

5 Small-Cap Biotechs With Big Potential

5 Small-Cap Biotechs With Big Potential

These 5 stocks all have positive catalysts on the horizon.

Amicus Therapeutics Expands Biologics Pipeline With New Preclinical Program For Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency

Amicus Therapeutics Expands Biologics Pipeline With New Preclinical Program For Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency

Potential First-in-Class Protein Replacement Therapy for Devastating Rare Genetic Neurological Disorder with No Approved Treatments

2 Small Biotech Stocks With Big Milestones

As Brexit turmoil calms down, let's get back to small cap stocks.

Commit To Buy Amicus Therapeutics At $3, Earn 18.3% Using Options

Commit To Buy Amicus Therapeutics At $3, Earn 18.3% Using Options

Investors considering a purchase of Amicus Therapeutics Inc stock, but cautious about paying the going market price of $6.02/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $3 strike, which has a bid at the time of this writing of 55 cents.

Relative Strength Alert For Amicus Therapeutics

Relative Strength Alert For Amicus Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Amicus Therapeutics Appoints Craig A. Wheeler To Board Of Directors

Amicus Therapeutics Appoints Craig A. Wheeler To Board Of Directors

Re-Elects John F. Crowley, Margaret G. McGlynn, Michael G. Raab, and Glenn P. Sblendorio

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering big breakout trades.

Oversold Conditions For Amicus Therapeutics (FOLD)

Oversold Conditions For Amicus Therapeutics (FOLD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Amicus Shares Barely Budge on Prediction of $3 Billion Buyout

Amicus Shares Barely Budge on Prediction of $3 Billion Buyout

Investors give the side eye to a prediction from Chardan analyst Gbola Amusa that Amicus Therapeutics will be acquired for three times its current market value

Amicus (FOLD) Stock Soars After EU Regulator Recommended Drug

Amicus (FOLD) Stock Soars After EU Regulator Recommended Drug

Amicus (FOLD) stock is surging this afternoon after a European regulator recommended approving the company's Fabry disease treatment.

Amicus Fabry Drug Takes Big Step Toward European Approval

Amicus Fabry Drug Takes Big Step Toward European Approval

A committee of European drug reviewers voted Friday to recommend the approval of the first oral treatment for Fabry disease, developed by Amicus Therapeutics.

6 Biotech Stocks Under $10 to Trade for Big Breakouts

6 Biotech Stocks Under $10 to Trade for Big Breakouts

These stocks trading for less than $10 a share are within range of triggering big breakout trades.

First Week of FOLD May 20th Options Trading

First Week of FOLD May 20th Options Trading

Investors in Amicus Therapeutics Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FOLD options chain for the new May 20th contracts and identified one put and one call contract of particular interest.